ThalesNano Receives the Millennium Award for Intellectual Property Strategy

May 22nd, 2009 – Budapest, Hungary, London, UK, Princeton, US – On April 24 ThalesNano Zrt. was honoured to receive the Millennium Award, established by the Hungarian Patent Office. The Board of Trustees, appointed by the Hungarian Patent Office, awards this accolade to institutions that play an especially important role in the protection of intellectual property.

The award was accepted by Dr. Ferenc Darvas, the Founder & Chairman. “Disruptive innovation in R&D is a integral part of the company’s accomplishments, both in the past and in the future”, said Dr. Darvas. “This award belongs to and recognizes the achivements of the entire research and development community at ThalesNano. Our corporate philosophy is to undertake our research and development with a high level of innovation that solves difficult customer problems. This is a key component in our company’s ability to develop and prosper. An integral component is the appropriate protection of intellectual property. Thanks to ThalesNano’s innovations and patents, we increased our revenue by 50 percent last year. We are very proud that we are an important supplier for nearly all of the major pharmaceutical and chemical companies worldwide including 20 out of the 20 of the world’s largest pharmaceutical companies”.

About ThalesNano Inc.
ThalesNano www.thalesnano.com is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Mid™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.
Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

Discovery of sleeping sickness cure aided by H-Cube®

May 8th, 2009 – A collaboration between groups led by Dr. John Spencer at Greenwich University in the UK and Professor Simon Mackay and Professor Alan Harvey at Strathclyde University in Scotland has led to the discovery of a novel class of benzodiazepines with submicromolar activity against trypanosoma brucei spp., a parasitic species that causes African trypanosomiasis or sleeping sickness in humans.

The work was helped by the use of a H-Cube® continuous-flow hydrogenation reactor used for hydrogenation and developed by ThalesNano, based in Budapest, Hungary.

Dr. John Spencer, Reader in Medicinal Chemistry, said: ‘Rajendra Rathnam, one of my PhD students at Greenwich, has successfully synthesised a number of benzodiazepine containing amines by a variety of reduction methods from their nitro precursors including microwave reductions with Molybdenum hexacarbonyl/DBU or Tin(II) Chloride, but the H-Cube® flow method provided compounds in approximately 5 minutes in high yields and without the need for work-up or column chromatography. Such an approach is very promising for the generation of libraries of bioactive molecules and can expedite drug discovery significantly.’

‘We are proud that our technology can play an important role in advancing science,’ said Richard Jones, Director of Product Management at ThalesNano.

‘From its introduction, H-Cube® has opened up vast new areas of chemistry due to its advantages of speed, selectivity and yield.’

University of Greenwich Expedites Drug Discovery with ThalesNano H-Cube®

May 7th, 2009 – Budapest, Hungary, London, UK, Princeton, US – A collaboration between groups led by Dr John Spencer at Greenwich University and Professor Simon Mackay and Professor Alan Harvey at Strathclyde University has led to the discovery of a novel class of benzodiazepines with submicromolar activity against trypanosoma brucei spp. a parasitic species that causes African trypanosomiasis or sleeping sickness in humans.

Dr. John Spencer, Reader in Medicinal Chemistry, said “Rajendra Rathnam, one of my PhD students at Greenwich, has successfully synthesized a number of benzodiazepine containing amines by a variety of reduction methods from their nitro precursors including microwave reductions with Mo(CO)6/DBU or SnCl2.2H2O, but the H-Cube® flow method provided compounds in approximately 5 minutes in high yields and without the need for work-up or column chromatography. Such an approach is very promising for the generation of libraries of bioactive molecules and can expedite drug discovery significantly”

The work was recently presented at the prestigious MedChem Europe 2009 Conference in Berlin (organized by Select Biosciences).

“We are proud that our technology can play an important role in advancing science said Richard Jones, Director of Product Management at ThalesNano. From its introduction, H-Cube® has opened up vast new areas of chemistry due to its advantages of speed, selectivity and yield.”

About ThalesNano Inc.

ThalesNano www.thalesnano.com is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow chemistry reactors. The company has the widest portfolio of bench-top continuous process chemistry instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi® are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500